Showing results (1-10 of 29) with videos related to
Sort By:
Pageof 3
Current Opinion in Physiology|July 29, 2021
Molecular mechanisms of retinal ischemiaSeth D Fortmann, Maria B GrantExpert Review of Cardiovascular Therapy|June 30, 2015
International central adjudication committee in the PLATO trial: independent body of experts or friendly family picnic?Victor L Serebruany, Seth D FortmannInternational Journal of Cardiology|September 5, 2015
The FDA report on vorapaxar in the elderly: A convoluted dilemmaVictor L Serebruany, Seth D FortmannInternational Journal of Cardiology|November 27, 2015
Vorapaxar and optimal aspirin dose: The FDA outlookVictor L Serebruany, Seth D Fortmann, Moo Hyun KimCardiology|October 22, 2015
Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? The Example of VorapaxarVictor L Serebruany, Seth D Fortmann, Moo Hyun KimThrombosis and Haemostasis|November 29, 2013
Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challengeVictor L Serebruany, Alex N Pokov, Seth D Fortmann, et al.American Journal of Therapeutics|March 8, 2017
Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?Victor L Serebruany, Seth D Fortmann, Daniel F Hanley, et al.Expert Review of Neurotherapeutics|November 14, 2015
Vorapaxar for secondary stroke prevention: perspectives and obstaclesVictor L Serebruany, Moo Hyun Kim, Seth D Fortmann, et al.Scientific Reports|April 25, 2018
Mousetap, a Novel Technique to Collect Uncontaminated Vitreous or Aqueous and Expand Usefulness of Mouse ModelsSeth D Fortmann, Valeria E Lorenc, Jikui Shen, et al.JCI Insight|September 22, 2017
Reversible retinal vessel closure from VEGF-induced leukocyte pluggingYuanyuan Liu, Jikui Shen, Seth D Fortmann, et al.Pageof 3